Neurotech Pharmaceuticals recently announced the first commercial manufacturing, shipment, and surgical procedure of the ...

Sruthi Arepalli, MD, an assistant professor at Emory Eye Center in Atlanta, Georgia, presented a comprehensive study on secondary lens implants in patients with uveitis at the 2025 ASRS meeting.

Panelists discuss how their management approach for geographic atrophy (GA) has evolved from a “come back in a year” mentality to actively offering treatment discussions within 2 to 3 months, with ...

Retina Group of WashingtonLai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor.

Lai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor. Michael Lai, MD, PhD, presented at the 2025 annual scientific meeting of the American ...

Topcon Healthcare enhances its connected care model by acquiring IRIS, integrating AI for improved diabetic eye disease screening and patient coordination.

Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025.

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

Ocugen recently announced new members of the Retina Scientific Advisory Board (SAB) and executive leadership team. 1 These updates support Ocugen's efforts to pursue its goal of 3 biologics license ...

Advertorial: Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy? The triad of inflammation, neuropathy, and vasculopathy plays a key role ...

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.